FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Alprolix Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
ALPROLIX™, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B (congenital Factor IX deficiency) for:
- Control and prevention of bleeding episodes,
- Perioperative management,
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
ALPROLIX™ is not indicated for induction of immune tolerance in patients with hemophilia B [see Warnings and Precautions (5.3)].
History
There is currently no drug history available for this drug.
Other Information
Coagulation Factor IX (Recombinant), Fc Fusion Protein [rFIXFc], the active ingredient in ALPROLIX™, is a recombinant coagulation Factor IX protein consisting of the human coagulation Factor IX sequence covalently linked to the Fc domain of human immunoglobulin G1 (IgG1). The Factor IX portion of rFIXFc has a primary amino acid sequence that is identical to the Thr148 allelic form of plasma derived Factor IX and has structural and functional properties similar to endogenous Factor IX. The Fc domain of rFIXFc contains the hinge, CH2, and CH3 regions of IgG1. rFIXFc contains 867 amino acids with a molecular weight of approximately 98 kilodaltons.
ALPROLIX™ is not derived from human blood and contains no preservatives. The recombinant Factor IX Fc fusion protein is expressed in a human embryonic kidney (HEK) cell line, which produces rFIXFc into a defined cell culture medium that does not contain proteins derived from animal or human sources. The purification process for rFIXFc does not include use of a monoclonal antibody reagent. To enhance viral safety, the purification process incorporates a nanofiltration step and a column chromatography purification step that have been validated for viral clearance. The content of activated Factor IX Fc fusion protein (FIXaFc) is limited to ≤0.035 mole percent FIXaFc/FIXFc.
ALPROLIX™ is a sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent, for intravenous injection. After reconstitution, the solution has a clear to slightly opalescent appearance and contains the excipients: sucrose, mannitol, sodium chloride, L-histidine and polysorbate 20. ALPROLIX™ is available in single-use vials containing the labeled amount of Factor IX activity, expressed in international units. Each vial contains nominally 500 IU, 1000 IU, 2000 IU or 3000 IU.
Sources
Alprolix Manufacturers
-
Biogen Idec Inc.
Alprolix | Biogen Idec Inc.
For intravenous use after reconstitution only
2.1 Dosing Guidelines Initiate treatment with ALPROLIX™ under the supervision of a qualified healthcare professional experienced in the treatment of hemophilia B. Dose and duration of treatment depend on the severity of the Factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition. Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency of ALPROLIX™ on the individual clinical response. Each vial label for ALPROLIX™ states the Factor IX potency in international units (IU). ALPROLIX™ potency is assigned using an in vitro, activated partial thromboplastin time (aPTT)-based, one-stage clotting assay calibrated against the World Health Organization (WHO) international standard for Factor IX concentrates. Factor IX activity measurements in the clinical laboratory may be affected by the type of aPTT reagent or laboratory standard used.[see Warnings and Precautions (5.4)]One IU of ALPROLIX™ per kg body weight increases the circulating level of Factor IX by 1% [IU/dL]. Estimate the required dose or the expected in vivo peak increase in Factor IX level expressed as IU/dL (or % of normal) using the following formulas:
IU/dL (or % of normal) =
[Total Dose (IU)/Body Weight (kg)] x Recovery (IU/dL per IU/kg)
OR
Dose (IU) =
Body Weight (kg) x Desired Factor IX Rise (IU/dL or,
% of normal) x Reciprocal of Recovery (IU/kg per IU/dL)
Dose adjustment may be necessary in pediatric patients under 12 years of age [see Use in Specific Populations (8.4)]. For patients 12 years of age or older, dose adjustment is not usually required.Control and Prevention of Bleeding Episodes
ALPROLIX™ dosing for the control and prevention of bleeding episodes is provided in Table 1.
Table 1: Dosing for Control and Prevention of Bleeding Episodes Type of Bleeding Circulating Factor IX Level
Required (IU/dL
or % of normal) Dosing Interval (hours) Minor and Moderate
For example: Uncomplicated hemarthroses, superficial muscle (except iliopsoas) without neurovascular compromise, superficial soft tissue, mucous membranes
30-60 Repeat every 48 hours if there is further evidence of bleeding Major
For example: Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss; Pharyngeal, retropharyngeal, retroperitoneal, CNS 80-100 Consider a repeat dose after 6-10 hours and then every 24 hours for the first 3 days.
Due to the long half-life of ALPROLIX™, the dose may be reduced and frequency of dosing may be extended after day 3 to every 48 hours or longer until bleeding stops and healing is achieved.Perioperative Management
ALPROLIX™ dosing for perioperative management is provided in Table 2 .
Table 2: Dosing for Perioperative Management Type of Surgery Circulating Factor IX Level
Required (IU/dL or % of normal) Dosing Interval (hours) Minor
(including uncomplicated dental extraction)
50 to 80 A single infusion may be sufficient. Repeat as needed after 24-48 hours until bleeding stops and healing is achieved. Major 60 to 100 (initial level)
Consider a repeat dose after 6-10 hours and then every 24 hours for the first 3 days.
Due to the long half-life of ALPROLIX™, the dose may be reduced and frequency of dosing in the post-surgical setting may be extended after day 3 to every 48 hours or longer until bleeding stops and healing is achieved.Routine Prophylaxis
The recommended starting regimens are either 50 IU/kg once weekly, or 100 IU/kg once every 10 days. Adjust dosing regimen based on individual response. 2.2 Reconstitution Use aseptic technique (clean and germ-free) and a flat work surface during the reconstitution procedure. Allow the vial of ALPROLIX™ and the pre-filled diluent syringe to reach room temperature before use. Remove the plastic cap from the vial and wipe the rubber stopper of the vial with an alcohol wipe. Allow the rubber stopper to dry. Completely remove the backing from the vial adapter package by peeling back the lid. Do not remove the vial adapter from the package or touch the inside of the package of the adapter.To combine two or more vials of ALPROLIX™, after step 12 above, follow these pooling steps:
Remove the diluent syringe from the vial adapter by turning it counterclockwise until it is completely detached. Do not detach the diluent syringe or the large luer lock syringe until ready to attach the large luer lock syringe to the next vial (with vial adapter attached). Leave the vial adapter attached to the vial, as it is needed for attaching a large luer lock syringe. Attach a separate, large luer lock syringe by turning clockwise until it is securely in place. Slowly pull on the plunger rod to draw the solution into the syringe. Repeat this pooling procedure with each vial necessary to obtain the required dose. Once you have pooled the required dose, proceed to administration using the large luer lock syringe. 2.3 AdministrationFor intravenous injection only
Inspect the reconstituted ALPROLIX™ solution visually for particulate matter and discoloration prior to administration. Do not use if particulate matter or discoloration is observed. Do not administer reconstituted ALPROLIX™ in the same tubing or container with other medications.Administration Steps:
Attach the syringe to the connector end of the infusion set tubing by turning clockwise until it is securely in place. Depress the plunger until all air is removed from the syringe and ALPROLIX™ has reached the end of the infusion set tubing. Do not push ALPROLIX™ through the needle. Remove the protective needle cover from the infusion set tubing. Perform intravenous bolus infusion. The rate of administration should be determined by the patient's comfort level, and no faster than 10 ml per minute.After infusing ALPROLIX™, remove and properly discard the infusion set.
Login To Your Free Account